- Home
- INCY vs CPT Comparison
INCY vs CPT Comparison
Compare INCY & CPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INCY
- CPT
- Stock Information
- Founded
- INCY 1991
- CPT 1993
- Country
- INCY United States
- CPT United States
- Employees
- INCY N/A
- CPT N/A
- Industry
- INCY Biotechnology: Commercial Physical & Biological Resarch
- CPT Real Estate Investment Trusts
- Sector
- INCY Health Care
- CPT Real Estate
- Exchange
- INCY Nasdaq
- CPT Nasdaq
- Market Cap
- INCY 13.4B
- CPT 12.2B
- IPO Year
- INCY 1993
- CPT 1993
- Fundamental
- Price
- INCY $58.98
- CPT $118.26
- Analyst Decision
- INCY Hold
- CPT Buy
- Analyst Count
- INCY 20
- CPT 19
- Target Price
- INCY $73.06
- CPT $128.55
- AVG Volume (30 Days)
- INCY 1.8M
- CPT 972.9K
- Earning Date
- INCY 04-29-2025
- CPT 05-01-2025
- Dividend Yield
- INCY N/A
- CPT 3.55%
- EPS Growth
- INCY N/A
- CPT N/A
- EPS
- INCY 0.10
- CPT 1.09
- Revenue
- INCY $4,413,226,000.00
- CPT $1,562,268,000.00
- Revenue This Year
- INCY $12.28
- CPT $2.10
- Revenue Next Year
- INCY $9.20
- CPT $3.59
- P/E Ratio
- INCY $611.49
- CPT $108.82
- Revenue Growth
- INCY 17.13
- CPT 0.55
- 52 Week Low
- INCY $52.81
- CPT $98.35
- 52 Week High
- INCY $83.95
- CPT $127.69
- Technical
- Relative Strength Index (RSI)
- INCY 44.09
- CPT 54.42
- Support Level
- INCY $57.77
- CPT $118.20
- Resistance Level
- INCY $62.87
- CPT $120.15
- Average True Range (ATR)
- INCY 1.78
- CPT 2.13
- MACD
- INCY 0.20
- CPT 0.72
- Stochastic Oscillator
- INCY 36.23
- CPT 61.81
About INCY Incyte Corp.
Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.
About CPT Camden Property Trust
Camden Property Trust is a real estate investment trust engaged in the ownership, management, development, reposition, redevelopment, acquisition, and construction of multifamily apartment communities. It owned interests in, operated, or developing nearly 177 multifamily properties comprised of nearly 59,996 apartment homes across the United States.